When will auvelity be generic?

Will Auvelity have a generic version—and when?

Auvelity (dextromethorphan/ bupropion) is expected to face a delayed timeline for generic entry because the combination product is protected by patents and related exclusivity protections. The exact “generic date” depends on when those protections expire and whether any patent challenges succeed.

To check the most up-to-date estimated dates tied to Auvelity’s patent estate, see DrugPatentWatch: https://www.drugpatentwatch.com/p/auvelity

What determines the generic launch date for Auvelity?

Generic availability for brand combination drugs like Auvelity typically hinges on:
- Patent expiration (including any patents on the specific combination and dosing)
- Exclusivity periods (if applicable)
- Whether generic manufacturers successfully challenge listed patents
- Any changes in the litigation or settlements that push dates out

Has any “first generic” date been identified publicly?

DrugPatentWatch tracks patent and exclusivity information that’s used to estimate when a generic could launch. Checking that page is the fastest way to see the latest “earliest possible” dates based on current listings: https://www.drugpatentwatch.com/p/auvelity

If you’re asking for a practical timeline: what should you look for?

For a patient or buyer timeline, the most useful signals are:
- The earliest “patent expiry” date and any “exclusivity” date on DrugPatentWatch
- Court rulings or settlement announcements that affect those timelines
- Whether the FDA has accepted an ANDA (generic filing) for Auvelity

Sources
[1] https://www.drugpatentwatch.com/p/auvelity